Merck Sharp & Dohme Corp. v. Albrecht
Headline: Drug labeling dispute: judges, not juries, decide when federal law blocks state failure-to-warn claims, and manufacturers must show the FDA knew and refused a required warning.
Holding: The Court held that whether federal law prevented a drug maker from adding a state-required warning is a question of law for a judge, and 'clear evidence' requires showing the FDA was fully informed and refused approval.
- Makes pre-emption decisions legal questions judges decide, not juries.
- Requires manufacturers to show FDA was fully informed and refused approval.
- Could increase uniformity in federal pre-emption rulings in drug cases.
Summary
Background
A large group of more than 500 people sued Merck after they suffered rare thigh-bone breaks they say were caused by long-term use of Fosamax and by the absence of a warning on its label. Fosamax was approved in 1995 without mentioning atypical femoral fractures. Over the next decade researchers, doctors, and Merck gathered reports and studies suggesting a possible link. In 2008 Merck sought changes to its label; the FDA approved an addition to the Adverse Reactions section but rejected Merck’s proposed Precautions language. Merck withdrew a formal application and used a different change process; the FDA ordered stronger warnings in 2011. Plaintiffs sued under state law, and courts disagreed about whether federal law barred those state claims.
Reasoning
The Court addressed who should decide whether federal law prevented a company from adding a state-required warning. It held that this is a question of law for a judge, not a jury. The Court explained that to show the kind of 'clear evidence' Wyeth referred to, a manufacturer must prove it fully informed the FDA of the reasons for the warning and that the FDA then told the manufacturer it would not approve the change. The Court said judges must ask whether federal and state requirements are truly irreconcilable, and it noted that only agency actions with the force of federal law can pre-empt state rules. The Court did not set an evidentiary standard like 'clear and convincing' and emphasized the FDA's CBE process that can let manufacturers add warnings pending review.
Real world impact
The ruling makes judges responsible for resolving pre-emption in drug-warning lawsuits, which should bring more uniform legal outcomes. Drug companies now face a clearer legal burden to show FDA disapproval before claiming federal pre-emption. This opinion decides the procedural question only and returns the case to the Court of Appeals for further proceedings.
Dissents or concurrances
Several Justices wrote separately: one stressed limits on pre-emption and said Merck’s defense likely fails, while another stressed factual details and highlighted the FDA’s duty to consider new safety information under later statutory provisions.
Opinions in this case:
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?